DIMA Biotechnology LTD is a biotechnology company specializing in membrane protein production and monoclonal antibody development. All our products are developed using our own proprietary platforms with a focus on druggable targets. We offer several solutions for full-length multipass transmembrane proteins including Membrane Nanoparticle (MNP), Virus-Like Particle (VLP), Exosome (EXO), Synthetic Nanodisc, and Detergent extraction. Most of our proteins are purified from mammalian cell expression systems and validated by functional assays and SDS-PAGE. We also have a proprietary single B cell cloning platform, DimAb® platform, for recombinant monoclonal antibody (mAb) development which can efficiently generate many diversified mAbs and acquire the antibody sequences in a high-throughput way. Combined with our antibody engineering and functional assay evaluation services, we can provide integrated solutions for scientific research, clinical diagnosis, and therapeutic R&D.